NCT00262925 2015-05-05Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 2 Terminated12 enrolled 6 charts